journal article·2018-03-12

Rational Design of an Amphiphilic Chlorambucil Prodrug Realizing Self-Assembled Micelles for Efficient Anticancer Therapy

Xu Hu, Ruiling Liu, Di Zhang, Jing Zhang, Zhonghao Li, Yuxia Luan

Publisher page

Abstract

The application of anticancer drug chlorambucil (CLB) in chemotherapy is severely restricted by its insolubility, lability, and toxic side effects; therefore, it is challenging to realize a highly efficient anticancer therapy of chlorambucil. To solve the above drawbacks encountered by chlorambucil, herein we proposed an amphiphilic chlorambucil prodrug-based self-assembled micelle strategy to realize the highly efficient anticancer therapy of chlorambucil. 1,6-Hexanediamine hydrochloride (HDH) serving as the hydrophilic segment was covalently bound to hydrophobic CLB to prepare an amphiphilic prodrug CLB-HDH which could self-assemble into micelles in aqueous solution. These micelles can passively target tumor tissues via the enhanced permeability and retention (EPR) effect, leading to enhanced cellular internalization. Both the cytotoxicity assay in vitro and anticancer study in vivo confirmed the excellent therapeutic activity of CLB-HDH micelles in comparison with free chlorambucil. Moreover, the hemolysis examination and histological analysis demonstrated the designed CLB-HDH micelles are safe in drug delivery. Therefore, our designed amphiphilic prodrug CLB-HDH micelles bring new opportunity for chlorambucil clinical application to combat cancers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, Jinan, Shandong Province 250012, P. R. China

Key Laboratory of Colloid & Interface Chemistry, Shandong University, Ministry of Education, Jinan, Shandong Province 250100, P. R. China

Funding

National Natural Science Foundation of China

References (59)

Show source-provided references
1. 10.1016/j.jconrel.2012.02.02010.1016/j.jconrel.2012.02.020 ↗
2. 10.1016/j.canlet.2012.08.02310.1016/j.canlet.2012.08.023 ↗
3. 10.1039/C6RA02051H10.1039/C6RA02051H ↗
4. 10.1016/j.jcis.2016.03.03910.1016/j.jcis.2016.03.039 ↗
5. 10.1021/ja505212y10.1021/ja505212y ↗
6. 10.1016/S0169-409X(97)00027-610.1016/S0169-409X(97)00027-6 ↗
7. 10.1039/C2TB00004K10.1039/C2TB00004K ↗
8. 10.1016/j.colsurfb.2016.02.04510.1016/j.colsurfb.2016.02.045 ↗
9. 10.1021/acs.biomac.5b0175810.1021/acs.biomac.5b01758 ↗
10. 10.1016/j.ijpharm.2016.10.02910.1016/j.ijpharm.2016.10.029 ↗
11. 10.1016/j.colsurfb.2016.12.01210.1016/j.colsurfb.2016.12.012 ↗
12. 10.1021/ja807416t10.1021/ja807416t ↗
13. 10.1039/C2CS35265F10.1039/C2CS35265F ↗
14. 10.1016/j.biomaterials.2013.03.09710.1016/j.biomaterials.2013.03.097 ↗
15. 10.1021/acs.molpharmaceut.5b0095210.1021/acs.molpharmaceut.5b00952 ↗
16. 10.1016/j.biomaterials.2012.06.04810.1016/j.biomaterials.2012.06.048 ↗
17. 10.1021/jm900091h10.1021/jm900091h ↗
18. 10.1016/j.nano.2014.09.01410.1016/j.nano.2014.09.014 ↗
19. 10.1002/adma.20110476310.1002/adma.201104763 ↗
20. 10.1016/j.jconrel.2004.12.01810.1016/j.jconrel.2004.12.018 ↗
21. 10.1002/anie.20080049110.1002/anie.200800491 ↗
22. 10.1016/j.ijpharm.2015.08.00610.1016/j.ijpharm.2015.08.006 ↗
23. 10.1016/j.tips.2014.09.00810.1016/j.tips.2014.09.008 ↗
24. 10.1002/adma.20150502510.1002/adma.201505025 ↗
25. 10.1021/acsami.6b0804410.1021/acsami.6b08044 ↗
26. 10.1056/NEJM20001214343240210.1056/NEJM200012143432402 ↗
27. 10.1016/S0006-2952(99)00142-210.1016/S0006-2952(99)00142-2 ↗
28. 10.1021/jm401243810.1021/jm4012438 ↗
29. 10.1080/1042819031000159570410.1080/10428190310001595704 ↗
30. 10.1016/j.ejmech.2017.05.05610.1016/j.ejmech.2017.05.056 ↗
31. 10.1002/jlcr.348110.1002/jlcr.3481 ↗
32. 10.1021/acsomega.6b0016710.1021/acsomega.6b00167 ↗
33. 10.1093/nar/15.24.1053110.1093/nar/15.24.10531 ↗
34. 10.1016/j.biomaterials.2016.11.02310.1016/j.biomaterials.2016.11.023 ↗
35. 10.1039/C6CC08977A10.1039/C6CC08977A ↗
36. 10.1016/j.ijpharm.2015.08.01110.1016/j.ijpharm.2015.08.011 ↗
37. 10.1016/j.ejps.2015.08.01310.1016/j.ejps.2015.08.013 ↗
38. 10.1016/j.ijpharm.2008.04.02710.1016/j.ijpharm.2008.04.027 ↗
39. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
40. 10.1016/j.nantod.2011.02.00310.1016/j.nantod.2011.02.003 ↗
41. 10.1016/j.drudis.2014.06.00410.1016/j.drudis.2014.06.004 ↗
42. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
43. 10.1016/j.cis.2006.01.00210.1016/j.cis.2006.01.002 ↗
44. 10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗
45. 10.1016/j.biomaterials.2013.03.03510.1016/j.biomaterials.2013.03.035 ↗
46. 10.1021/am303073u10.1021/am303073u ↗
47. 10.1016/j.jconrel.2016.03.03710.1016/j.jconrel.2016.03.037 ↗
48. 10.1016/j.biomaterials.2015.05.04610.1016/j.biomaterials.2015.05.046 ↗
49. 10.1016/j.phrs.2013.01.00910.1016/j.phrs.2013.01.009 ↗
50. 10.1016/j.biomaterials.2016.01.04910.1016/j.biomaterials.2016.01.049 ↗
51. 10.1016/j.biomaterials.2016.07.00210.1016/j.biomaterials.2016.07.002 ↗
52. 10.1039/C3CC47427E10.1039/C3CC47427E ↗
53. 10.1021/nn103419710.1021/nn1034197 ↗
54. 10.1016/j.ijpharm.2016.06.13910.1016/j.ijpharm.2016.06.139 ↗
55. 10.1021/bc200410d10.1021/bc200410d ↗
56. 10.1002/smll.20110000110.1002/smll.201100001 ↗
57. 10.1021/nn302503s10.1021/nn302503s ↗
58. 10.1021/bc800068h10.1021/bc800068h ↗
59. 10.1021/ma101316w10.1021/ma101316w ↗